Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7782563 | 0.79 | DAO (0.56) | TAAR1DAO | |
| SCHEMBL28127868 | 0.72 | DAO (0.50) | HRH3TAAR1DAOABL1RIN1 | |
| SCHEMBL1628817 | 0.71 | ABL1 (0.55) | HRH3TAAR1DAOABL1RIN1 | |
| SCHEMBL1034848 | 0.69 | HRH3 (1.00) | HRH3TAAR1SMN1; SMN2CYP2D6 | |
| SCHEMBL5907151 | 0.69 | AOC3 (0.56) | DAOSMN1; SMN2HCAR2AOC3ADORA1 | |
| SCHEMBL1584769 | 0.67 | DAO (0.53) | DAOSMN1; SMN2HCAR2HPGDADORA1 | |
| SCHEMBL9878574 | 0.66 | POLB (0.61) | DAOSMN1; SMN2HCAR2CAPN1HPGD | |
| SCHEMBL29903956 | 0.66 | AOC3 (0.47) | HRH3TAAR1DAOSMN1; SMN2HCAR2 | |
| SCHEMBL10936216 | 0.64 | HCAR2 (0.50) | HRH3TAAR1DAOHCAR2TSHR | |
| SCHEMBL13757285 | 0.64 | DAO (0.49) | HRH3TAAR1DAOSMN1; SMN2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996041634-A2 | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN ASSOCIATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC S.C.R.L. (IT) | 1996-12-27 | — | — | WO | claimed |
| EP-3125894-B1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-7928086-B2 | Administering a beta -L-2'-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug therapy of a host infected with a drug-resistant form of HBV that exhibits a mutation at the 552 codon from methionine to valine in the DNA polymerase region | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| US-7585851-B2 | 3′-prodrugs of 2′-deoxy-β-L-nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1572095-A4 | S-L-2 -DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1296995-B1 | 3'-PRODRUGS OF 2'-DEOXY-BETA-L-NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-10-15 | — | — | EP | disclosed |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2002040021-A2 | METHODS FOR INHIBITING THE TRANSMISSION OF HIV USING TOPICALLY APPLIED SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES | IDENIX (CAYMAN) LIMITED (KY) | 2002-05-23 | — | — | WO | disclosed |
| WO-2001096353-A2 | 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2001-12-20 | — | — | WO | disclosed |
| CN-1309647-A | Substd. 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions contg. them | NOVIRIO PHARMACEUTICALS LTD (KY) | 2001-08-22 | — | — | CN | disclosed |
| CN-1309647-A | Substd. 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions contg. them | NOVIRIO PHARMACEUTICALS LTD (KY) | 2001-08-22 | — | — | CN | disclosed |
| EP-1098887-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Novirio Pharmaceuticals Limited (KY) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003998-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-01-27 | — | — | WO | disclosed |
| WO-1996041634-A3 | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN ASSOCIATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | SARDINIAN ANTIVIRAL RESEARCH C (IT) | 1997-01-23 | — | — | WO | disclosed |
| WO-1996041634-A2 | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN ASSOCIATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC S.C.R.L. (IT) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996041634-A2 | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN ASSOCIATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC S.C.R.L. (IT) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996010565-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ISTITUTO SUPERIORE DI SANITA' (IT) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | HRH3 4335/4885TAAR1 4360/4885DAO 545/4885 |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | SLC28A2, SLC28A1, SLC29A2 | HRH3 4343/4885TAAR1 4263/4885DAO 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.